In this randomized phase II multicenter study, we examined short course chemotherapy and the potential of RT in improving the efficacy of CPI.Methods:This was a multicenter study of FOLFOX + Nivo for 3 months followed by maintenance Nivo with or without RT (20Gy in 5 fractions to the ...
作者: CHECKMATE-9X8[11]研究探索了纳武利尤单抗+ mFOLFOX6/贝伐珠单抗(NIVO+SOC)对比mFOLFOX6/贝伐珠单抗(SOC)一线治疗mCRC的疗效。纳武利尤单抗组的ORR为60%,SOC组为46%[11],两组的中位PFS均为11.9个月。纳武利尤单抗组的中位OS为29.2个月,SOC组未达到。该研究探索性亚组分析表明,纳武利尤单抗治疗12个月...
Additional studies,those will compare nivoluma plus TOGA regime versus TOGA regime(SOC) are required..1.Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. Firstline pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction ...
4045 Background: FOLFOX plus nivolumab (nivo) has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas. FL... S Lorenzen,T Goetze,R Hofheinz,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 196PThe tolerability and efficacy of...
LBA38_PR - CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30: v874–v875. doi:10.1093/annonc/mdz394.029 19. Finn RS, Ryoo ...
4045 Background: FOLFOX plus nivolumab (nivo) has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas. FL... S Lorenzen,T Goetze,R Hofheinz,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 196PThe tolerability and efficacy of...
4045 Background: FOLFOX plus nivolumab (nivo) has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas. FL... S Lorenzen,T Goetze,R Hofheinz,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 196PThe tolerability and efficacy of...
4045 Background: FOLFOX plus nivolumab (nivo) has become standard of care for first-line therapy of patients (pts) with esophagogastric adenocarcinomas. FL... S Lorenzen,T Goetze,R Hofheinz,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 196PThe tolerability and efficacy of...
LBA38_PR - CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30: v874–v875. doi:10.1093/annonc/mdz394.029 19. Finn RS, Ryoo ...